Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.74 |
| ▸ | GRM5 | P41594 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7025926 | 0.92 | ITGB3 (0.89) | ITGB3ITGA2BGRM5 | |
| SCHEMBL7332899 | 0.85 | ITGB3 (1.00) | ITGB3ITGA2BGRM5 | |
| Trifluoroacetic Acid SCHEMBL7032202 | 0.84 | ITGB3 (0.74) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7030491 | 0.83 | ITGB3 (0.57) | ITGB3ITGA2BGRM5 | |
| Trifluoroacetic Acid SCHEMBL7025929 | 0.80 | ITGB3 (0.62) | ITGB3ITGA2BGRM5 | |
| Trifluoroacetic Acid SCHEMBL7025715 | 0.79 | ITGB3 (0.88) | ITGB3ITGA2B | |
| SCHEMBL7343076 | 0.78 | ITGB3 (0.82) | ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL7035525 | 0.77 | ITGB3 (0.89) | ITGB3ITGA2B | |
| SCHEMBL504362 | 0.77 | ITGB3 (0.69) | ITGB3ITGA2BGRM5 | |
| Trifluoroacetic Acid SCHEMBL7029866 | 0.76 | ITGB3 (0.89) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135045-A1 | Glycoprotein IIb/IIIa antagonists | FISHER MATTHEW J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0635492-B1 | Glycoprotein IIb/IIIa antagonists | LILLY CO ELI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6137002-A | USEFUL FOR PREVENTION OF THROMBOSIS; FOR TREATING ATHEROSCLEROSIS AND ARTERIOSCLEROSIS, ACUTE MYOCARDIAL INFARCTION, CHRONIC STABLE ANGINA, UNSTABLE ANGINA, TRANSIENT ISCHEMIC ATTACKS AND STROKES, PERIPHERAL VASCULAR DISEASE, | ELI LILLY AND COMPANY (US) | 2000-10-24 | — | — | US | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5618843-A | INHIBIT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0635492-A1 | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135045-A1 | Glycoprotein IIb/IIIa antagonists | GP6, TBXA2R, ITGA2B | ITGB3 14/4885ITGA2B 3/4885GRM5 1608/4885 |
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | ITGB3 653/4885ITGA2B 294/4885GRM5 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.